engage checkpoint medical linkedin twitter

Current perspectives on TRK fusion-positive thyroid cancers

Current perspectives on TRK fusion-positive thyroid cancers

Clinical summary video and slides

Clinical summary video and slides

Prof. Ezra Cohen

In this 5-min video update, Prof. Ezra Cohen summarises current perspectives on the diagnosis and treatment of TRK fusion-positive cancers. He discusses US and European guidelines, two recent key publications and larotrectinib data presented at the American Thyroid Association annual meeting.


Clinical takeaways:

  • NTRK fusions are more common in paediatric compared to adult thyroid cancers, testing is warranted in both populations
  • NTRK2 fusions have not been seen in thyroid cancer, only NTRK1 and NTRK3 fusions
  • Larotrectinib and entrectinib are two approved TRK inhibitors showing durable responses with favourable safety profiles
  • There are differences in the prognosis of NTRK1 vs NTRK3 fusion-positive thyroid cancer and differentiated vs anaplastic thyroid cancers
Portrait of Ezra Cohen
Prof. Ezra Cohen

Medical Oncologist

Moores Cancer Center, San Diego

United States (US)

preview next

NTRK fusions in thyroid cancer

time | open 5 min | Dec 2022

This programme was made for you:   your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

This educational programme is supported by an Independent Medical Education Grant from Bayer

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca and Bayer.

Other programmes of interest